Department of Radiation Oncology, McGill University Health Centre, Montreal, Canada.
Intermediate-risk prostate cancer has been treated in many ways; the most effective treatment is uncertain. Hypofractionated external beam radiotherapy (HyRT) is a short and convenient alternative treatment. We report our results of HyRT in intermediate-risk patients.
Eighty two patients with intermediate-risk prostate cancer were treated with 3-dimensional conformal HyRT plans to the dose of 66Gy/22 fractions prescribed at the isocenter without hormones. Intermediate-risk was defined as clinical stage T2b-T2c, or pre-treatment PSA between 10 and 20ng/mL, or Gleason Score equal 7. The planning target volume consisted of the prostate plus a uniform 7mm margin. Toxicity was prospectively graded by the Common Terminology Criteria version3. Biochemical relapse was defined as post-radiotherapy nadir PSA+2ng/mL.
With a median follow-up of 51months, 5-year actuarial biochemical recurrence free survival is 95.4%. At the last follow-up visit, grade ⩾2 late gastro-intestinal and genito-urinary toxicity rates were 2% and 7%, respectively. No patient ever developed grade 4 or 5 toxicity.
HyRT to a dose of 66Gy in 22 fractions as a single treatment modality is convenient for patients and for the health care system and appears to provide similar results to other treatment choices.
Faria S, Pra AD, Cury F, David M, Duclos M, Freeman CR, Souhami L. Are you the author?
Reference: Radiother Oncol. 2011 Aug 22. Epub ahead of print.